Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alcohol Dependence Treatment Vivitrol “Approvable”

This article was originally published in The Pink Sheet Daily

Executive Summary

Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.

You may also be interested in...



Vivitrol Approved Labeling Leaves Room For Broad Marketing Plan

Naltrexone is the first FDA-approved extended-release monthly alcohol dependence drug, Alkermes and Cephalon say.

Vivitrol Approved Labeling Leaves Room For Broad Marketing Plan

Naltrexone is the first FDA-approved extended-release monthly alcohol dependence drug, Alkermes and Cephalon say.

Alkermes Submits Vivitrol Complete Response

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS061460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel